Oxeladin

DB04822ApprovedWithdrawnSmall molecule

Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity.

Mechanism: Pharmacologically active on Sigma non-opioid intracellular receptor 1
Curator reviewed
Formula / weight: C₂₀H₃₃NO₃ · 335.4809 g/mol (avg)

Resolves to

Compound

Clinical / RWD

Structure

InChIKeyIQADUMSPOQKAAO-UHFFFAOYSA-NSMILESCCN(CC)CCOCCOC(=O)C(CC)(CC)C1=CC=CC=C1

Targets

What you can answer from here — as of August 30, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1ATC codeIncluding every combination product, plus 5 drug categories

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Oxeladin, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.